Conclusion: While the pharmacy cost was higher for abatacept compared to adalimumab driven by the rebate, due to its higher clinical efficacy, the CPR was consistently lower for SE+ RA patients treated with abatacept. The results may be useful for US healthcare decision makers in understanding how to optimize treatment for SE+ RA patient while minimizing costs in today's budget constrained environment.

Proportion of responders at 24 weeks by treatment

Figure 1. Proportion of responders by treatment data from the Early AMPL study

References:

Disclosure of Interests: Sang Hee Park Consultant of: Pharmerit International, which received consultancy fees from Bristol-Myers Squibb (US), Employee of: Bristol-Myers Squibb (US), Sakina Nanji Consultant of: Pharmerit International, which received consultancy fees from Bristol-Myers Squibb (US), Inc. for this study, Yuxuan Yan of: Bristol-Myers Squibb (US), Employee of: Bristol-Myers Squibb (US), Inc. for this study, Dipo Patel Consultant of: Pharmerit International, which received consultancy fees from Bristol-Myers Squibb (US), Inc. for this study, Dipo Patel Consultant of: Pharmerit International, which received consultancy fees from Bristol-Myers Squibb (US), Inc. for this study.

Conclusion: A monitoring cap seems a simple instrument to measure adherence. However, multiple steps and a lot of time are needed to come to a workable dataset for the study of adherence patterns.

Acknowledgments: The GLORIA project is funded by the European Union's Horizon 2020 research and innovation programme under the topic "Personalizing Health and Care", grant agreement No 634886.